Skip to main content
Oxford Research Peptides
RESEARCH PRIMER

The Incretin Effect Explained

A foundation guide to incretin biology — the physiological basis on which GLP-1 receptor agonist and dual/triple agonist research is built.

QUICK ANSWER
TL;DR

Quick answer

The incretin effect describes the observation that oral glucose provokes a substantially larger insulin response than an equivalent intravenous glucose challenge. Two gut-derived peptides mediate this effect: glucagon-like peptide-1 (GLP-1), released from intestinal L-cells, and glucose-dependent insulinotropic polypeptide (GIP), released from K-cells. Both amplify glucose-dependent insulin secretion from pancreatic β-cells and together account for a large fraction of postprandial insulin release in healthy individuals.
EXTENDED ANSWER
AI-ready

Extended answer

What is the incretin effect and why does it matter?

The incretin effect describes the observation that oral glucose provokes substantially more insulin secretion than an equivalent intravenous glucose challenge. Two gut peptides mediate it: glucagon-like peptide-1 (GLP-1) released from intestinal L-cells, and glucose-dependent insulinotropic polypeptide (GIP) released from K-cells. Both amplify glucose-dependent insulin secretion from pancreatic β-cells at class B G-protein-coupled receptors, and GLP-1 additionally suppresses glucagon secretion, slows gastric emptying and modulates central appetite pathways. Native GLP-1 has a plasma half-life of only one to two minutes because it is rapidly cleaved by DPP-4 — the fundamental problem long-acting analogues such as Semaglutide were engineered to solve. Understanding incretin biology is foundational to interpreting the pharmacology of every GLP-1 receptor agonist and every dual or triple agonist that builds on this class.
KEY FACTS

Key facts

Incretin peptides
GLP-1 and GIP
GLP-1 source
Intestinal L-cells (distal small intestine and colon)
GIP source
Intestinal K-cells (proximal small intestine)
Primary effect
Glucose-dependent amplification of insulin secretion
Native GLP-1 half-life
≈ 1–2 minutes (DPP-4 cleavage)

Historical observation

Classical experiments showed that a defined oral glucose load triggered substantially more insulin secretion than the same amount of glucose delivered intravenously to produce comparable plasma glucose levels. The difference — attributed to gut-derived signals released during nutrient absorption — was named the incretin effect.[4]

The two incretin hormones

  • GLP-1 (glucagon-like peptide-1) — a 30- or 31-residue peptide cleaved from proglucagon in intestinal L-cells and released in response to carbohydrate and lipid absorption.
  • GIP (glucose-dependent insulinotropic polypeptide) — a 42-residue peptide released from intestinal K-cells in response predominantly to carbohydrate and lipid ingestion.

Effects on pancreatic islets

Both incretins act at class B G-protein-coupled receptors on pancreatic β-cells to amplify glucose-dependent insulin secretion. GLP-1 additionally suppresses glucagon secretion from α-cells in a glucose-dependent manner. The strict glucose-dependence of these effects is central to the low intrinsic hypoglycaemia risk of GLP-1-based pharmacology.[3]

Extra-pancreatic effects of GLP-1

GLP-1 signalling is not confined to the islet. GLP-1 receptors are expressed in gastrointestinal smooth muscle (slowing gastric emptying), in vagal afferents and in the central nervous system, where distributed brainstem and hypothalamic populations integrate satiety signals.[4]

Why native incretins are short-lived

Both GLP-1 and GIP are cleaved rapidly by dipeptidyl peptidase-4 (DPP-4). Native GLP-1 has a plasma half-life of only one to two minutes. Long-acting GLP-1 receptor agonists such as Semaglutide overcome this by combining a DPP-4-resistant substitution with a fatty-acid side chain that supports albumin binding.[1][2]

Why the incretin effect matters for research

Every GLP-1 receptor agonist, GLP-1/GIP dual agonist and GLP-1/ GIP/glucagon triple agonist is designed against a specific view of incretin biology. Interpreting in-vitro assay data, receptor pharmacology and pathway readouts for these compounds requires the incretin framework as background.

Research-use framing

This is a foundation science primer. It is not clinical guidance on diabetes or metabolic disease. See Research Use Only.

Related reading: Semaglutide monograph, What is Semaglutide, Semaglutide mechanism of action, GLP-1 receptor explained, Retatrutide monograph, Triple agonists explained, Research Use Only and Testing & Quality Control.

References12

  1. 1.

    Lau J, Bloch P, Schäffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.. Journal of Medicinal Chemistry. 2015;58(18):7370-7380.

    DOI: 10.1021/acs.jmedchem.5b00726PMID: 26308095
  2. 2.

    Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide.. Frontiers in Endocrinology. 2019;10:155.

    DOI: 10.3389/fendo.2019.00155PMID: 31031702
  3. 3.

    Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.. Cell Metabolism. 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001PMID: 29617641
  4. 4.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.. Gastroenterology. 2007;132(6):2131-2157.

    DOI: 10.1053/j.gastro.2007.03.054PMID: 17498508
  5. 5.

    Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).. New England Journal of Medicine. 2016;375(19):1834-1844.

    DOI: 10.1056/NEJMoa1607141PMID: 27633186
  6. 6.

    Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity (STEP 1).. New England Journal of Medicine. 2021;384(11):989-1002.

    DOI: 10.1056/NEJMoa2032183PMID: 33567185
  7. 7.

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT).. New England Journal of Medicine. 2023;389(24):2221-2232.

    DOI: 10.1056/NEJMoa2307563PMID: 37952131
  8. 8.

    Husain M, Birkenfeld AL, Donsmark M, et al.. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6).. New England Journal of Medicine. 2019;381(9):841-851.

    DOI: 10.1056/NEJMoa1901118PMID: 31185157
  9. 9.

    Buckley ST, Bækdal TA, Vegge A, et al.. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.. Science Translational Medicine. 2018;10(467):eaar7047.

    DOI: 10.1126/scitranslmed.aar7047PMID: 30429357
  10. 10.

    de Graaf C, Donnelly D, Wootten D, et al.. Glucagon-like peptide-1 and its class B G protein–coupled receptors.. Pharmacological Reviews. 2016;68(4):954-1013.

    DOI: 10.1124/pr.115.011395PMID: 27736833
  11. 11.

    Gabery S, Salinas CG, Paulsen SJ, et al.. Semaglutide lowers body weight in rodents via distributed neural pathways.. JCI Insight. 2020;5(6):e133429.

    DOI: 10.1172/jci.insight.133429PMID: 32213703
  12. 12.

    Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW).. New England Journal of Medicine. 2024;391(2):109-121.

    DOI: 10.1056/NEJMoa2403347PMID: 38785209
EVIDENCE SUMMARY
Evidence

Evidence summary

Strong evidence
Research confidenceHigh confidence
The incretin effect and the roles of GLP-1 and GIP are supported by decades of peer-reviewed physiology and pharmacology literature.
RESEARCH LIMITATIONS

Research limitations

  • The relative contribution of GLP-1 vs GIP to the postprandial incretin effect varies between individuals and physiological states.
  • Extrapolation from healthy human physiology to disease states (e.g. type 2 diabetes, obesity) is not always direct.
  • Peripheral vs central effects of GLP-1 signalling in vivo cannot be fully separated in most experimental designs.
RELATED GUIDES
COMPOUND REFERENCE
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-10-01
Updated
2026-10-01
Reviewed
2026-10-01
Version
1.0

Revision history

  1. v1.02026-10-01· Editorial Team

    Authority Sprint 2C — depth publication: pharmacokinetics, research applications, albumin binding and incretin effect.

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-04-01. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-10-01Updated: 2026-10-01